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A determinação espectroscópica multivariada da associação lamivudina-zidovudina foi 
realizada por regressão de mínimos quadrados parciais. O modelo foi desenvolvido a partir de 
20 misturas sintéticas utilizando-se dados espectrais centrados na média adquiridos entre 190 e 
350 nm e 3 variáveis latentes. A validação externa foi realizada a partir de 6 misturas sintéticas, 
observando-se erros médios de previsão de aproximadamente 1%. Na análise de medicamentos 
foram obtidos bons resultados, com erros de previsão inferiores a 10%. A metodologia multivariada 
foi validada de acordo com os critérios do International Conference on Harmonization (ICH), 
demonstrando precisão, exatidão e robustez compatíveis com a legislação vigente.
The multivariate spectroscopic determination of lamivudine-zidovudine associations was 
carried out by partial least square regression (PLS). This model was developed from 20 synthetic 
mixtures using mean-centered spectral data acquired from 190 to 350 nm and with 3 latent 
variables. External validation was performed with 6 synthetic mixtures providing prediction errors 
close to 1%. Moreover, the analysis of commercial drugs showed good results with prediction 
errors lower than 10%. The multivariate methodology was validated according to International 
Conference on Harmonization (ICH) criteria, demonstrating precision, accuracy and robustness 
within legal requirements. 
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Introduction
Electronic spectroscopy is an analytical technique of 
recognized importance, mainly due to its low instrumental 
and operational costs, high analytical throughput, and 
a sensitivity that meets many analytical requirements. 
Unfortunately, its low selectivity hinders many applications, 
which is a consequence of the frequently observed spectral 
interferences.1,2
In the pharmaceutical industry, for instance, there is a 
need for fast and accurate analytical methods, mainly for the 
establishment of routines governing the analytical control 
of raw materials and products. Many pharmaceutical 
products contain the association of two or more drugs 
with a great number of auxiliary substances (excipients), 
a fact that increases both the complexity of the matrix 
and the difficulty of applying spectroscopic methods. 
Consequently, many analytical routines are based on 
chromatographic methods, which are relatively expensive 
and time-consuming.3 
In light of these facts, the development of strategies 
to overcome the problem of spectral interferences is 
important, especially to improve the analytical potential 
of the electronic spectroscopy. With this purpose in mind, 
there are several alternatives that can be used, including the 
preliminary separation of the analyte from the interfering 
matrix,4 the chemical derivatisation of the analyte 
(formation of a derivative that absorbs in a non-interfering 
spectral region),5 the application of spectral derivative 
methods,6 and the use of multivariate calibration tools.7 
Recently, several reports on the spectroscopic 
determination of drugs in pharmaceutical formulations 
by using partial least squares regression (PLS) have been 
published.1,8-10 The results from these reports attest to the 
suitability of the chemometric approach for the resolution 
of complex multicomponent mixtures.
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The aim of this study is the development of a new analytical 
methodology for the quality control of pharmaceutical 
formulations containing lamivudine and zidovudine using 
UV-Vis spectroscopy and partial least squares regression. 
Zidovudine (AZT, 3’-azido-3’-deoxythymidine) and 
lamivudine (3TC, 2’-deoxy-3’-thiacytidine) are synthetic 
nucleoside analogues with activity against the human 
immunodeficiency virus (HIV). AZT and 3TC are frontline 
therapies for the treatment of HIV infection and have become 
available in a combination tablet, containing 300 mg of AZT 
and 150 mg of 3TC per dose.11
Typically, the quantification of AZT and 3TC in 
pharmaceutical formulations is carried out by liquid 
chromatography according to official protocols from 
the United States Pharmacopoeia.12 Additionally, several 
chromatographic methods based on UV-Vis detection have 
been recently validated,13-15 including micellar electrokinetic 
chromatography (MEKC)16 and high performance thin-
layer chromatography (HPTLC).17 
Even with several reports attesting to the suitability of 
multivariate spectroscopic routines for the quality control 
of pharmaceutical products,7 studies involving AZT-3TC 
associations were not found in the current specialized 
literature. To the best of our knowledge, just one article 
reported the spectrophotometric determination of this 
association using a derivative method.18 
Experimental
Reagents 
Zidovudine and lamivudine were kindly provided by 
Cristália Produtos Químicos e Farmacêuticos Ltda. (Itapira, 
SP, Brazil) with a purity of 99%. Stock solutions were 
prepared by direct dissolution of the drugs in deionised 
water.
The reference (Biovir, GlaxoSmithKline Brasil Ltda, Rio 
de Janeiro, RJ, Brazil) and generic (zidovudine/lamivudine, 
Farmanguinhos Laboratory, Rio de Janeiro, RJ, Brazil) 
drugs, containing 300 mg of AZT and 150 mg of 3TC each, 
were purchased from a local drugstore in Brazil.
 Acetonitrile (JT Baker), methanol (Merck) and 
deionised water (Milli-Q®, Millipore, Billerica, MA, 
USA) were of HPLC grade. Other chemicals were of 
analytical/reagent grade.
Equipments and software
Electronic absorption measurements were carried out 
on a Shimadzu (2410 PC, Kyoto, Japan) spectrophotometer 
using 1.00 cm quartz cells. The spectral data were recorded 
between 190 and 300 nm using a spectral resolution of 
0.5 nm (221 points per spectrum).
High performance liquid chromatography (HPLC) 
analyses were carried out on a Varian 920-LC analytical 
chromatograph equipped with an autosampler, a quaternary 
gradient pump and a UV-Vis detector (265 nm). Routine 
chromatographic separations were performed on a Varian 
Cromosorb C18 column (5 mm, 250 × 4.6 mm). 
The data treatment was carried out using Origin Pro 6.1 
software (OriginLab). PLS models were developed by using 
PLS-Toolbox 3.0 (Eigenvector Research, Inc.) operating in 
Matlab 6.5 (Math Work Inc.).
Procedures
Conventional calibration 
Initially, three conventional calibration systems were 
developed by using six synthetic mixtures containing 10.00 
to 35.00 mg L-1 of zidovudine and 5.00 to 20.00 mg L-1 of 
lamivudine in deionised water. Individual analytical graphs 
(method 1) were elaborated by plotting the absorbance 
registered at the maximum absorption wavelength 
(266.0 nm for zidovudine and 197.0 nm for lamivudine) 
against the concentration of the standard solutions. In the 
derivative mode (method 2), the analytical graphs were 
created in a similar way, using the first-derivative signal 
registered for zidovudine at the zero-crossing wavelength 
of lamivudine and vice versa. The third conventional 
methodology (method 3) involved Vierordt’s method,19 
which is based on the additivity of the Lambert-Beer’s 
law. The absorbance of the mixed samples was measured 
at two suitable wavelengths, and the concentration of each 
compound was calculated from the following equations: 
A (266 nm) = (aAZT, 266 nm × CAZT) + (a3TC, 266 nm × C3TC)  (1)
A (271 nm) = (aAZT, 271 nm × CAZT) + (a3TC, 271 nm × C3TC)  (2)
where A denotes the absorbance of the mixture, a is the 
absorption coefficient (L mg-1 cm-1), optical path is 1.00 cm 
and and C is the concentration (mg L-1).
The predictive capacity of these conventional calibration 
methods was evaluated by analysing six synthetic mixtures, 
containing 19.00 to 29.00 mg L-1 of zidovudine and 11.00 
to 13.00 mg L-1 of lamivudine.
Multivariate calibration 
Multivariate calibration models were developed with 
20 synthetic mixtures containing 19.00 to 29.00 mg L-1 of 
zidovudine and 10.00 to 14.00 mg L-1 of lamivudine (Figure 1). 
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The modelling amplitude was chosen taking into account 
the nominal concentration of AZT and 3TC in commercial 
medications (sample 13) and a maximal variation of ± 20%. 
Additionally, six synthetic mixtures were prepared and 
reserved as an external validation set (Figure 1).
Several signal pre-treatment systems were evaluated, 
including mean-centered, Savitski-Golay smoothing and 
first derivative. The number of latent variables (LV) was 
chosen taking into account the minimization of the root 
mean standard error of cross validation (RMSECV) value, 
a parameter calculated from the results of a leave-one-out 
cross-validation routine (equation 3). To avoid the creation 
of over-fitted models, a minimum number of latent variables 
was preferred, avoiding values with low captured variance. 
 (3)
where yi and ^yi represent the real and estimated 
concentrations, respectively.
Validation
The validation of the spectroscopic multivariate 
model was carried out according to guidelines from the 
International Conference on Harmonization (ICH),20 
which includes evaluations of precision, accuracy, 
linearity and robustness. Precision was appraised at two 
different levels (intra-day repeatability and inter-day 
intermediate precision) by triplicate analysis of three 
synthetic mixtures containing high (AZT: 29.0 mg L-1, 
3TC: 14.0 mg L-1), medium (AZT: 24.0 mg L-1, 3TC: 
12.0 mg L-1) and low (AZT: 19.0 mg L-1, 3TC: 10.0 mg L-1) 
analyte concentrations. Accuracy was evaluated by recovery 
studies using the same three synthetic mixtures. Finally, 
the robustness of the method was evaluated by analysis 
of one synthetic mixture containing 24.0 mg L-1 of AZT 
and 12.0 mg L-1 of 3TC in several pH values (3.2 to 10.1), 
temperature (5 to 60 oC) and measurement time (0 to 90 h) 
conditions.
Analysis of commercial drugs 
Twenty tablets were individually weighed to obtain 
their representative average weights (774.1 mg) and then 
finely powdered and mixed. For spectroscopic analysis, 
a quantity of the powder equivalent in mass to one tablet 
was accurately weighed and dissolved in 1000.0 mL of 
deionised water. An aliquot of 2.0 mL was transferred to 
a 25.0 mL volumetric flask and filled up to the mark with 
deionised water. The spectra were obtained using the same 
conditions described previously.
For chromatographic analysis, a quantity of the powder 
equivalent in mass to one tablet was accurately weighed 
and dissolved in 100.0 mL of methanol. An aliquot of 
0.2 mL was transferred to a 25.0 mL volumetric flask and 
filled up to the mark with (methanol:water:acetonitrile, 
49:44:7 v/v/v) mobile phase. The chromatographic 
determinations were performed under isocratic conditions, 
using the procedure described by Uslu and Özkan18 with 
modifications. All analyses were carried out in triplicate.
Results and Discussion
Conventional calibration
The significant spectral interference between AZT and 
3TC is clearly evident in the spectral data shown in Figure 2. 
In the first analysis, the serious overlap observed in the zero-
order spectra hinders the simultaneous determination of 
AZT and 3TC, which emphasizes the necessity of a more 
discriminating calibration system. The great similarity 
between the spectral data of commercial drugs and synthetic 
mixtures, however, indicates an insignificant spectral 
interference from chemical excipients, which suggests the 
suitability of current calibration models. 
Three conventional calibration systems were used 
to determine the concentrations of AZT and 3TC in six 
synthetic mixtures. The results (Table 1) confirmed bad 
predictions of the models constructed from zero-order 
spectra (method 1), due to the spectral interference earlier 
mentioned. Under these conditions, relative mean errors 
higher than 50% were routinely observed for both drugs. 
Figure 1. Synthetic mixtures of AZT and 3TC used as calibration and 
external validation sets in the development of multivariate calibration 
models. 
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The development of individual analytical models based 
on first-derivative spectra (method 2) reduces the prediction 
errors, mainly for AZT determinations. Even when the 
spectral interference is minimized by working at zero-
crossing wavelengths, the mean relative prediction error 
observed in the 3TC determinations was still very high 
(about 30%). This result was probably the consequence of 
the decreased sensitivity and signal/noise ratio, which are 
both characteristics of derivative methods. Processing the 
data by Savitzki-Golay smoothing drastically reduced the 
prediction errors to approximately 2%. 
Upon the application of the conventional methodology 
based on Vierordt’s method (method 3), a good predictive 
capacity was observed for AZT. In contrast, 3TC 
determination by this method leads to mean errors (10.8%) 
that are incompatible with Brazilian legislation21 which 
requires a maximal discrepancy of 5%.
Multivariate calibration
Several multivariate models were developed using three 
pre-processing systems and different numbers of latent 
variables (Table 2). With six synthetic mixtures used as an 
external validation set, low prediction errors were observed 
in all conditions, a result that demonstrated the ability 
of the PLS-2 algorithm to overcome problems related to 
overlapped spectral signals. For subsequent studies, the 
model developed using three latent variables and mean-
centered spectral signals was selected, mainly due to the 
lower prediction errors observed at these conditions (AZT: 
1.26%; 3TC: 0.87%).
The RMSECV evolution as a function of the number 
of latent variables (LVs) is shown in Figure 3. According 
to the data in this figure, the introduction of two latent 
variables (LVs) significantly reduces the RMSECV value, 
improving the prediction capacity of the multivariate 
model. Moreover, the variance captured by the first two LVs 
represents 99.64% of the total variance of the Y block (AZT 
and 3TC concentrations) and 99.95% of the total variance of 
the X block (spectral data). The introduction of a third LV 
contributes 0.01% of the spectral data variance, increasing 
the total captured variance of the Y block up to 99.79%.
The great similarity observed between the loading 
of the first LV (Figure 4) and the spectral profile of 3TC 
(Figure 2), and between the loading of the second LV and 
the spectral data of AZT, implies that practically all relevant 
spectral information associated with 3TC (and AZT) can 
be captured by just one latent variable, which results 
from the linear combination of the original variables. The 
presence of outliers was evaluated by examination of the 
Figure 2. Spectral profiles of aqueous solutions of AZT, 3TC, synthetic 
mixture and commercial drug.
Table 1. Relative mean errors (n = 6) in the determination of AZT and 3TC in synthetic mixtures from the validation set by conventional calibration systems
Calibration method r (wavelength) Relative mean error (%)
AZT 3TC AZT 3TC
Method 1 0.999 (266.5 nm) 0.999 (197.0 nm) 55.2 66.5
Method 2 0.998 (248.8 nm) 0.997 (266.2 nm) 2.0 27.5
Method 2 (with smoothing) 0.998 (248.8 nm) 0.997 (266.2 nm) 2.1 2.3
Method 3 - - 3.8 10.8
r = regression coefficient; Method 1: Individual analytical graphs based on zero-order spectra. Method 2: Individual analytical graphs based on first-
derivative spectra. Method 3: Vierordt’s method. 
Table 2. Relative mean errors (n = 6) in the determination of AZT 
and 3TC in synthetic mixtures from the validation set by multivariate 
calibration systems
LV Number
Pre-processing
Mean centered Smoothed and first derivate
AZT 3TC AZT 3TC
2 1.25 1.93 1.54 1.62
3 1.26 0.87 1.40 1.52
4 1.43 0.97 1.38 1.05
6 1.49 0.86 1.47 1.11
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Studentized residues versus leverage graphs (results not 
shown). Considering limiting values of ± 2.5 and 3(LV)/n, 
respectively, anomalies were not observed in the calibration 
set. Finally, the prediction capacity of the multivariate 
model was appraised in regards to the external validation 
set (RMSEP: 0.3527 for AZT and 0.1168 for 3TC) and the 
cross-validation routine (RMSECV: 0.1553 for AZT and 
0.1734 for 3TC). The results (Figure 5) indicated good 
prediction capacity with correlation coefficients (r) higher 
than 0.994 in all cases.
The best multivariate model, developed from mean-
centered spectral signals and using 3 latent variables, was 
applied to the analysis of commercial drugs containing 
the AZT/3TC association. The results (Table 3) from this 
model indicated a good agreement between multivariate 
and chromatographic methods, with maximum relative 
errors lower that 10%. 
Validation of the multivariate methodology
The spectroscopic multivariate methodology was 
validated according to guidelines from the ICH, which 
included precision, accuracy, linearity and robustness 
assessments. Repeatability and intermediate precision 
evaluations showed relative standard deviations (RSD) 
Figure 3. Evolution of the RMSECV value and the captured variance 
(inner table) as a function of the number of latent variables.
Figure 4. Loading for LV1 and LV2 in multivariate models developed 
with mean centered spectral data.
Figure 5. Correlation between real and predicted concentration of AZT 
and 3TC in validation (cross and external) and calibration sets. 
Table 3. Results from the chromatographic and multivariate spectroscopic determinations of AZT and 3TC in commercial formulations
Commercial 
Drug
Nominal concentration 
(mg L-1)
Predicted concentration (mg L-1) (relative standard deviation)
Error (%)
HPLC Multivariate model
AZT 3TC AZT 3TC AZT 3TC AZT 3TC
Reference 24.00 12.00 21.07 (1.28) 12.17 (1.04) 21.59 (0.58) 11.40 (0.15) 2.47 -6.36
Generic 23.04 (1.66) 11.75 (0.78) 21.08 (0.31) 10.57 (0.33) -8.51 -10.04
Prediction error calculated with respect to the HPLC result.
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Table 4. Results of the precision and accuracy evaluations
Repeatability
Zidovudine Lamivudine
Real 
(mg L-1)
Predicted 
(mean, n = 3)
RSD 
(%)
Recovery 
(%)
Real 
(mg L-1)
Predicted 
(mean, n = 3)
RSD 
(%)
Recovery 
(%)
19.00 19.54 0.06 102.84 10.00 9.91 0.31 99.10
24.00 23.87 0.07 99.46 12.00 11.70 0.24 97.50
29.00 28.83 0.08 99.41 14.00 13.70 0.07 97.86
Mean 0.07 100.57 Mean 0.21 98.15
Intermediate precision
Zidovudine Lamivudine
Real 
(mg L-1)
Predicted 
(mean, n = 6)
RSD 
(%)
Recovery 
(%)
Real 
(mg L-1)
Predicted 
(mean, n = 6)
RSD 
(%)
Recovery 
(%)
19.00 19.79 0.28 104.18 10.00 9.93 0.20 99.30
24.00 24.43 0.64 101.79 12.00 11.64 0.39 97.00
29.00 29.11 0.33 100.38 14.00 13.69 0.10 97.79
Mean 0.42 102.12 Mean 0.23 98.03
RSD = relative standard deviation.
Table 5. Evaluation of the robustness considering the effect of temperature, measurement time and pH on the prediction capacity of the multivariate 
methodology 
Temperature
Zidovudine Lamivudine
Real Concentration (mg L-1) 24.00 12.00
Temperature (ºC) 5, 10, 15, 20, 25, 30, 40 and 60 
Average Predicted Concentration (mg L-1) 23.17 11.98
Mean Error (%) 3.46 0.17
RSD (%) 1.54 2.77
Measurement time
Zidovudine Lamivudine
Real Concentration (mg L-1) 24.00 12.00
time (h) 0, 17, 56 and 90
Average Predicted Concentration (mg L-1) 23.40 11.71
Mean Error (%) 2.49 2.42
RSD(%) 0.46 0.27
pH
Zidovudine Lamivudine
Real Concentration (mg L-1) 24.00 12.00
Preditect concentration in mg L-1 (Error in %)
pH 3 32.23 (34.29) 7.31 (-39.09)
pH 5 24.72 (2.99) 11.33 (-5.62)
pH 6 24.15 (0.62) 12.11 (0.93)
pH 7 22.36 (-6.82) 11.28 (-5.98)
pH 9 21.28 (-11.35) 10.94 (-8.81)
pH 10 23.07 (-3.86) 7.90 (-34.13)
RSD = relative standard deviation.
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lower than 0.5% (Table 4), values in accordance with 
Brazilian legislation21 which demands a maximum RSD 
of 5%. The accuracy of the method was also confirmed 
through recovery tests (Table 4), with results from 97.79 
to 104.18%.
As it can be observed in Table 5, the results of the 
proposed methodology were not significantly modified by 
deliberate changes of the temperature and measurement 
time. In general, RSD values lower than 3% were observed 
between measurements carried out in different conditions. 
In contrast, changes to the pH of the samples led to higher 
RSD values, mainly due to modifications of the spectral 
profile of the drugs. AZT and 3TC have pKa values of 
9.8 and 4.3, respectively, a fact that implies significant 
modification of the protonation equilibrium in pH values 
higher than 9.8 or lower than 4.3. As expected from these 
observations, the prediction capacity of the multivariate 
methodology was seriously reduced at alkaline (pH 10) or 
acidic (pH 3) conditions, with prediction errors higher that 
30%. The precision capacity was observed to improve when 
working between pH 5 and 7, with prediction errors lower 
than 7%. Very low prediction errors were observed at pH 
6 (< 1%), which corresponds to the pH of the calibration 
samples.
Conclusions
The spectral interference observed between lamivudine 
and zidovudine hinders the analysis of associations of 
these two compounds by conventional external calibration 
systems. This spectral overlap can be overcome by using 
smoothed and first-derivative signals, a pre-processing 
system that generates prediction errors lower than 2.5% 
in the external validation process. In addition, multivariate 
models elaborated with mean-centered signals and using 
3 latent variables have prediction errors lower than 1.3% 
in the external validation process. In terms of the analysis 
of commercial drug associations, prediction errors lower 
than 10% were routinely observed, in relation to results 
from the standard chromatographic method. Validation 
studies have shown precision and accuracy results that are 
compatible with Brazilian legislation for the determination 
of lamivudine/zidovudine associations. 
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